1. Home
  2. RFL vs LUNG Comparison

RFL vs LUNG Comparison

Compare RFL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.22

Market Cap

63.5M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.33

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
LUNG
Founded
2017
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.5M
72.2M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
RFL
LUNG
Price
$1.22
$1.33
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
68.9K
715.9K
Earning Date
03-16-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
28.28
7.64
EPS
N/A
N/A
Revenue
$917,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
43.96
8.01
52 Week Low
$1.12
$1.13
52 Week High
$3.19
$7.01

Technical Indicators

Market Signals
Indicator
RFL
LUNG
Relative Strength Index (RSI) 41.84 42.68
Support Level $1.15 N/A
Resistance Level $1.59 $1.93
Average True Range (ATR) 0.09 0.11
MACD -0.01 -0.01
Stochastic Oscillator 7.41 32.87

Price Performance

Historical Comparison
RFL
LUNG

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: